Literature DB >> 28433373

Preimplantation genetic diagnosis for aneuploidy testing in women older than 44 years: a multicenter experience.

Filippo Maria Ubaldi1, Danilo Cimadomo2, Antonio Capalbo3, Alberto Vaiarelli4, Laura Buffo5, Elisabetta Trabucco6, Susanna Ferrero7, Elena Albani8, Laura Rienzi3, Paolo E Levi Setti8.   

Abstract

OBJECTIVE: To report laboratory and clinical outcomes in preimplantation genetic diagnosis for aneuploidies (PGD-A) cycles for women 44 to 47 years old.
DESIGN: Multicenter, longitudinal, observational study.
SETTING: In vitro fertilization (IVF) centers. PATIENT(S): One hundred and thirty-seven women aged 44.7 ± 0.7 years (range: 44.0-46.7) undergoing 150 PGD-A cycles during April 2013 to January 2016. INTERVENTION(S): Quantitative polymerase chain reaction-based PGD-A on trophectoderm biopsies and cryopreserved euploid single-embryo transfer (SET). MAIN OUTCOMES MEASURE(S): Primary outcome measure: delivery rate per cycle; secondary outcome measures: miscarriage rate, and the rate and reasons for cycle cancelation with subanalyses for female age and number of metaphase 2 oocytes retrieved. RESULT(S): In 102 (68.0%) of 150 cycles blastocyst development was obtained, but only 21 (14.0%) were euploid blastocysts. The overall euploidy rate was 11.8% (22 of 187). Twenty-one SET procedures were performed, resulting in 13 clinical pregnancies, of which 1 miscarried and 12 delivered. The delivery rate was 57.1% per transfer, 8.0% per cycle, and 8.8% per patient. The logistic regression analysis found that only female age (odds ratio 0.78) and number of metaphase 2 oocytes retrieved (odds ratio 1.25) statistically significantly correlated with the likelihood of delivery. The delivery rate per cycle was 10.6% (11 of 104) in patients aged 44.0 to 44.9 years and 2.6% in patients aged 45.0 to 45.9 years (n = 1 of 38). No euploid blastocysts were found for patients older than 45.0 years. CONCLUSION(S): Extensive counseling based on biological and clinical data should be provided to women older than 43 years who are requesting IVF because of their very low odds of success and high risk for embryonic aneuploidies. Nevertheless, the low miscarriage and good delivery rates reported in this study in women with good ovarian reserve aged 44 should encourage the use of PGD-A in this population.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced maternal age; IVF; PGD-A; PGS; poor prognosis

Mesh:

Year:  2017        PMID: 28433373     DOI: 10.1016/j.fertnstert.2017.03.007

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  27 in total

1.  The cost of a euploid embryo identified from preimplantation genetic testing for aneuploidy (PGT-A): a counseling tool.

Authors:  Randi H Goldman; Catherine Racowsky; Leslie V Farland; Janis H Fox; Santiago Munné; Lia Ribustello; Elizabeth S Ginsburg
Journal:  J Assist Reprod Genet       Date:  2018-07-31       Impact factor: 3.412

2.  One thousand seventy-eight autologous IVF cycles in women 45 years and older: the largest single-center cohort to date.

Authors:  Vinay Gunnala; Mohamad Irani; Alexis Melnick; Zev Rosenwaks; Steven Spandorfer
Journal:  J Assist Reprod Genet       Date:  2017-11-16       Impact factor: 3.412

3.  Donor egg is the best second choice for many infertile couples: real progress in overcoming age-related fertility is not here yet.

Authors:  Reeva Makhijani; Daniel R Grow
Journal:  J Assist Reprod Genet       Date:  2020-07-11       Impact factor: 3.412

4.  Pregnancy and neonatal outcomes of morphologically grade CC blastocysts: are they of clinical value?

Authors:  Menghui Li; Mingru Yin; Ling Wu; Zhiguang Yan; Qifeng Lyu; Zheng Yan; Bin Li
Journal:  Arch Gynecol Obstet       Date:  2020-08-11       Impact factor: 2.344

5.  Next-generation sequencing analysis of each blastomere in good-quality embryos: insights into the origins and mechanisms of embryonic aneuploidy in cleavage-stage embryos.

Authors:  Qiuwen Shi; Ying Qiu; Changlong Xu; Hua Yang; Chunyuan Li; Nina Li; Yumei Gao; Caiyun Yu
Journal:  J Assist Reprod Genet       Date:  2020-05-22       Impact factor: 3.412

6.  Second stimulation in the same ovarian cycle: an option to fully-personalize the treatment in poor prognosis patients undergoing PGT-A.

Authors:  Alberto Vaiarelli; Danilo Cimadomo; Gianluca Gennarelli; Maurizio Guido; Carlo Alviggi; Alessandro Conforti; Claudia Livi; Alberto Revelli; Silvia Colamaria; Cindy Argento; Maddalena Giuliani; Carlo De Angelis; Maria Matteo; Stefano Canosa; Angela D'Alfonso; Valentino Cimadomo; Laura Rienzi; Filippo Maria Ubaldi
Journal:  J Assist Reprod Genet       Date:  2022-02-07       Impact factor: 3.412

7.  Preimplantation Genetic Testing for Aneuploidy Improves Clinical, Gestational, and Neonatal Outcomes in Advanced Maternal Age Patients Without Compromising Cumulative Live-Birth Rate.

Authors:  Laura Sacchi; Elena Albani; Amalia Cesana; Antonella Smeraldi; Valentina Parini; Marco Fabiani; Maurizio Poli; Antonio Capalbo; Paolo Emanuele Levi-Setti
Journal:  J Assist Reprod Genet       Date:  2019-11-12       Impact factor: 3.412

8.  Minimizing mosaicism: assessing the impact of fertilization method on rate of mosaicism after next-generation sequencing (NGS) preimplantation genetic testing for aneuploidy (PGT-A).

Authors:  Katherine L Palmerola; Sally F Vitez; Selma Amrane; Catha P Fischer; Eric J Forman
Journal:  J Assist Reprod Genet       Date:  2018-10-25       Impact factor: 3.412

9.  Embryonic Development in Relation to Maternal Age and Conception Probability.

Authors:  Oshrit Lebovitz; Mediea Michaeli; Nardin Aslih; Diana Poltov; Daniela Estrada; Yuval Atzmon; Einat Shalom-Paz
Journal:  Reprod Sci       Date:  2021-02-16       Impact factor: 3.060

10.  Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Alessandro Conforti; Sandro C Esteves; Peter Humaidan; Salvatore Longobardi; Thomas D'Hooghe; Raoul Orvieto; Alberto Vaiarelli; Danilo Cimadomo; Laura Rienzi; Filippo Maria Ubaldi; Fulvio Zullo; Carlo Alviggi
Journal:  Reprod Biol Endocrinol       Date:  2021-06-21       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.